
CLAIMS:

1. A compound of formula **I**, or a pharmaceutically acceptable salt or solvate thereof:




(I)


wherein:

**$R_1$** is hydrogen, $C_1$-$C_6$ alkyl, partially or fully deuterated $C_1$-$C_6$ alkyl, $C_3$-$C_6$ cycloalkyl, $C_2$-$C_6$ cyanoalkyl, $C_1$-$C_6$ mercaptoalkyl or amino;

**$R_2$** is hydrogen or $C_1$-$C_3$ alkyl;

**$R_3$** is hydrogen or oxo;

or **$R_2$** and **$R_3$** combine to form a structure of formula **Ia**:




(Ia),

wherein:

**X** is **$CH_2$**, **$CR_6$** or **N**;

 is a double bond when **X** is **$CR_6$** or **N** and is a single bond when **X** is **$CH_2$**;


**$R_4$** is hydrogen or $C_1$-$C_3$ alkyl;

**$R_5$** is hydrogen or $C_1$-$C_2$ alkyl;

or **$R_4$** and **$R_5$** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the **$CH_2$** moiety is optionally substituted with two deuterium atoms;

**$R_6$** is hydrogen;

**A** is $C_5$-$C_7$ cycloalkyl, furanyl, thiophenyl, methylthiophenyl or




,

wherein:

**$X_1$** is hydrogen, halo or methyl;

**$X_1$'** is hydrogen or halo;

**$X_2$** is hydrogen, halo or methyl;


**$X_2$'** is hydrogen or halo;

**$X_3$** is hydrogen or fluoro;

**n** is 0 or 1, and when n is 0 a single or double bond joins the carbon atoms to which **$R_3$** and **$R_4$** are attached

for use in therapy.

2. A compound of formula **I**, or a pharmaceutically acceptable salt or solvate thereof:




(I),


wherein:

**$R_1$** is hydrogen, $C_1$-$C_6$ alkyl, partially or fully deuterated $C_1$-$C_6$ alkyl, $C_3$-$C_6$ cycloalkyl, $C_2$-$C_6$ cyanoalkyl, $C_1$-$C_6$ mercaptoalkyl or amino;

**$R_2$** is hydrogen or $C_1$-$C_3$ alkyl;

**$R_3$** is hydrogen or oxo;

or **$R_2$** and **$R_3$** combine to form a structure of formula **Ia**:




(Ia),

wherein:

**X** is **$CH_2$**, **$CR_6$** or **N**;

------ is a double bond when **X** is **$CR_6$** or **N** and is a single bond when **X** is **$CH_2$**;


**$R_4$** is hydrogen or $C_1$-$C_3$ alkyl;

**$R_5$** is hydrogen or $C_1$-$C_2$ alkyl;

or **$R_4$** and **$R_5$** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the $CH_2$ moiety is optionally substituted with two deuterium atoms;

**$R_6$** is hydrogen;

**A** is $C_5$-$C_7$ cycloalkyl, furanyl, thiophenyl, methylthiophenyl or




,

wherein:

**$X_1$** is hydrogen, halo or methyl;

**$X_1$'** is hydrogen or halo;


**$X_2$** is hydrogen, halo or methyl;

**$X_2$'** is hydrogen or halo;

**$X_3$** is hydrogen or fluoro;

**n** is 0 or 1, and when n is 0 a single or double bond joins the carbon atoms to which **$R_3$** and **$R_4$** are attached

with the proviso that the following compounds are excluded:



.


3. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein:

**$R_2$** is hydrogen or $C_1$-$C_3$ alkyl; and

**$R_3$** is hydrogen or oxo.

4. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein:

**$R_2$** and **$R_3$** combine to form a structure of formula **Ia**:




(Ia),

wherein:

**X** is **$CH_2$**, **$CR_6$** or **N**;


 is a double bond when **X** is **$CR_6$** or **N** and is a single bond when **X** is **$CH_2$**.

5. A compound for use in therapy according to claim 4, or a compound according to claim 4, wherein  is a double bond and **X** is **$CR_6$**.

6. A compound for use in therapy according to claims 1 or 3 to 5, or a compound according to claims 2 to 5, wherein n is 0 and a single bond joins the carbon atoms to which **$R_3$** and **$R_4$** are attached.


7. A compound for use in therapy according to claims 1 or 3 to 6, or a compound according to claims 2 to 6, wherein **$R_4$** and **$R_5$** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the **$CH_2$** moiety is optionally substituted with two deuterium atoms.

8. A compound for use in therapy according to claims 1 or 3 to 7, or a compound according to claims 2 to 7, wherein more than 50% of substituents **$R_5$** and **A** have the stereochemical configuration of formula **Id**





(Id)

9. A compound for use in therapy according to claims 1 or 3 to 7, or a compound according to claims 2 to 7, wherein more than 50% of substituents **R5** and **A** have the stereochemical configuration of formula **Ie**




(Ie)

10. A compound for use in therapy according to claims 1 or 3 to 9, or a compound according to claims 2 to 9, wherein **A** is




,

wherein **X1**, **X1'**, **X2**, **X2'** and **X3** are as defined in claim 1.

11. A compound for use in therapy according to claims 1 or 3 to 10, or a compound according to claims 2 to 10, wherein **R1** is hydrogen, methyl, *d3*-methyl, propyl, cyclopropyl, cyanomethyl, mercaptoethyl or amino.


12. A compound for use in therapy according to claims 3 or 6 to 11, or a compound according to claims 3 or 6 to 11, wherein **R2** is hydrogen or methyl.

13. A compound for use in therapy according to claims 3 or 6 to 12, or a compound according to claims 3 or 6 to 12, wherein **R3** is hydrogen.

14. A compound for use in therapy according to claims 1, 3 to 6 or 8 to 13, or a compound according to claims 2 to 6 or 8 to 13, wherein **$R_4$** is hydrogen or methyl.

15. A compound for use in therapy according to claims 1, 3 to 6 or 8 to 14, or a compound according to claims 2 to 6 or 8 to 14, wherein **$R_5$** is hydrogen or methyl.

16. A compound for use in therapy according to claims 1 or 3 to 15, or a compound according to claims 2 to 15, wherein **A** is




,

wherein:

**$X_1$** is hydrogen, fluoro, chloro or methyl;

**$X_1$'** is hydrogen, fluoro or chloro;

**$X_2$** is hydrogen, fluoro, chloro, bromo or methyl;

**$X_2$'** is hydrogen, fluoro, chloro or bromo;


**$X_3$** is hydrogen or fluoro.

17. A compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of conditions ameliorated by inhibition of dopamine-beta-hydroxylase within the central nervous system.


18. Use of a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treatment of conditions ameliorated by inhibition of dopamine-beta-hydroxylase within the central nervous system.

19. A pharmaceutical composition comprising (i) a therapeutically effective amount of a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof; and (ii) a pharmaceutically acceptable excipient.


20. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is selected from the group consisting of:




,




,




,




,




,




,





, and





or a pharmaceutically acceptable salt or solvate thereof.

21. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is





, or a pharmaceutically acceptable salt or solvate thereof.

22. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is





, or a pharmaceutically acceptable salt or solvate thereof.

23. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is





, or a pharmaceutically acceptable salt or solvate thereof.

24. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is





, or a pharmaceutically acceptable salt or solvate thereof.

25. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is





, or a pharmaceutically acceptable salt or solvate thereof.

26. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is





, or a pharmaceutically acceptable salt or solvate thereof.

27. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.

28. A compound for use in therapy according to claim 1, or a compound according to claim 2, wherein the compound is




, or a pharmaceutically acceptable salt or solvate thereof.